WALTHAM, Mass.--(BUSINESS WIRE)--May 12, 2021-- PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.
The Cellaca MX High-throughput Cell Counter from Nexcelom Bioscience has been nominated for a Scientists’ Choice Award
We are delighted to announce that, thanks to our loyal customers, the Cellaca™ MX High-throughput Cell Counter has been nominated in the Life Sciences category.
Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high throughput, high-speed automated cell counter – Cellaca™ MX.
The latest news from Nexcelom Bioscience March 20, 2018 - Nexcelom Bioscience announces strategic growth investment from Ampersand Capital Partners (PDF) March 20, 2018, Lawrence, MA -- Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom’s worldwide growth initiatives. Founded in 2003, Nexcelom is a fast-growing supplier of innovative cellular analysis instruments, software and related consumables used in a broad range of research fields including immuno-oncology, cell therapy, drug discovery, [...]
On February 9, 2016 at the Institute for Cancer Research, Chelsea, London, UK, Nexcelom will be holding an inaugural Celigo user group meeting, free to anyone who would like to attend. Celigo users from the pharmaceutical, academic, and biotech sectors will be present to discuss their research with this instrument. Speakers will include: Dr. Daniel Paull – NYSCF Dr. Maria Vinci – ICR Dr. Urs Senn – ETH Zurich Dr. Henning Gram Hansen – DTU Dr. Thilo Riedl – Genmab Dr. Valerie LeFourn – Selexis Dr. Christian Muller – Universite de Strasbourg The Celigo is a best-in-class image cytometer, with [...]